Chargement en cours...
The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study
Levomilnacipran (1S, 2R-milnacipran) is a potent and selective serotonin and norepinephrine reuptake inhibitor that is Food and Drug Administration approved for once-daily treatment of major depressive disorder in adults. Secondary and post-hoc analyses were carried out on data from a positive 10-we...
Enregistré dans:
| Publié dans: | Int Clin Psychopharmacol |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Lippincott Williams And Wilkins
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4235391/ https://ncbi.nlm.nih.gov/pubmed/24172160 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/YIC.0000000000000009 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|